The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences

References

• AuriemmaRSGaldieroMDe MartinoMCThe kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remissionEur J Endocrinol201016261035104220356933
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRGrassoLFDeterminants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey studyEur J Endocrinol2011165571372121868601
   PubMed Web of Science ®Google Scholar
• MelmedSCasanuevaFFKlibanskiAA consensus on the diagnosis and treatment of acromegaly complicationsPituitary201316329430222903574
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoASheppardMCStephensJMPulgarSMelmedSClinical, quality of life, and economic value of acromegaly disease controlPituitary201114328429421597975
   PubMed Web of Science ®Google Scholar
• HoldawayIMRajasooryaRCGambleGDFactors influencing mortality in acromegalyJ Clin Endocrinol Metab200489266767414764779
   PubMed Web of Science ®Google Scholar
• DekkersOMBiermaszNRPereiraAMRomijnJAVandenbrouckeJPMortality in acromegaly: a metaanalysisJ Clin Endocrinol Metab2008931616717971431
   PubMed Web of Science ®Google Scholar
• SherlockMWoodsCSheppardMCMedical therapy in acromegalyNat Rev Endocrinol20117529130021448141
   PubMed Web of Science ®Google Scholar
• HoldawayIMBollandMJGambleGDA meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegalyEur J Endocrinol20081592899518524797
   PubMed Web of Science ®Google Scholar
• AdelmanDTLiebertKJNachtigallLBLamersonMBakkerBAcromegaly: the disease, its impact on patients, and managing the burden of long-term treatmentInt J Gen Med20136313823359786
   PubMedGoogle Scholar
• CarmichaelJDBonertVSNuñoMLyDMelmedSAcromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments – a meta-analysisJ Clin Endocrinol Metab20149951825183324606084
   PubMed Web of Science ®Google Scholar
• CostelloKKennedyPScanzilloJRecognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long termMedscape J Med200810922519008986
   PubMedGoogle Scholar
• PyatakEAFlorindezDWeigensbergMJAdherence decision making in the everyday lives of emerging adults with type 1 diabetesPatient Prefer Adherence2013770971823935361
   PubMed Web of Science ®Google Scholar
• BevanJSNewell-PriceJWassJAHome administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effectiveClin Endocrinol (Oxf)200868334334917892497
   PubMed Web of Science ®Google Scholar
• SalvatoriRNachtigallLBCookDMSALSA Study GroupEffectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegalyPituitary201013211512219898989
   PubMed Web of Science ®Google Scholar
• KasukiLMarquesNVNuezMJLealVLChinenRNGadelhaMRAcromegalic patients lost to follow-up: a pilot studyPituitary201316224525022821645
   PubMed Web of Science ®Google Scholar
• SalvatoriRWoodmanseeWWMolitchMGordonMBLomaxKGLanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registryPituitary2014171132123314980
   PubMed Web of Science ®Google Scholar
• GurelMHBrueningPRRhodesCLomaxKGPatient perspectives on the impact of acromegaly: results from individual and group interviewsPatient Prefer Adherence20148536224453479
   PubMedGoogle Scholar
• SmrtkaJCaonCSaundersCBeckerBLBaxterNEnhancing adherence through educationJ Neurosci Nurs2010425 supplS19S2921049830
   PubMed Web of Science ®Google Scholar
• LinnAJvan WeertJCSchoutenBCSmitEGvan BodegravenAAvanDLWords that make pills easier to swallow: a communication typology to address practical and perceptual barriers to medication intake behaviorPatient Prefer Adherence2012687188523271896
   PubMed Web of Science ®Google Scholar
• WhiteCPWhiteMRussellCSMultiple sclerosis patients talking with healthcare providers about emotionsJ Neurosci Nurs20073928910117477223
   PubMedGoogle Scholar
• SaundersCCaonCSmrtkaJShoemakerJFactors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosisJ Neurosci Nurs2010425 supplS10S1821049829
   PubMed Web of Science ®Google Scholar
• MartinLRWilliamsSLHaskardKBDimatteoMRThe challenge of patient adherenceTher Clin Risk Manag20051318919918360559
   PubMedGoogle Scholar
• BrownRFButowPNDunnSMTattersallMHPromoting patient participation and shortening cancer consultations: a randomised trialBr J Cancer20018591273127911720460
   PubMed Web of Science ®Google Scholar
• GrantRWAdamsASBaylissEAHeislerMEstablishing visit priorities for complex patients: a summary of the literature and conceptual model to guide innovative interventionsHealthcare (Amst)201313–4117122
   Google Scholar
• ColaoACannavòSMarzulloPTwelve months of treatment with octreotide-LAR reduces joint thickness in acromegalyEur J Endocrinol20031481313812534355
   PubMed Web of Science ®Google Scholar
• ColaoAMarzulloPFeroneDCardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegalyJ Clin Endocrinol Metab20008593132314010999798
   PubMed Web of Science ®Google Scholar
• ColaoATerzoloMBondanelliMGH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatmentClin Endocrinol (Oxf)200869461362018410555
   PubMed Web of Science ®Google Scholar
• WagnerEHAustinBTVon KorffMOrganizing care for patients with chronic illnessThe Milbank Quarterly74Hoboken, NJWiley19965115448941260
   PubMedGoogle Scholar
• ColaoAFeroneDMarzulloPLong-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegalyJ Clin Endocrinol Metab20018662779278611397887
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRRosatoFFirst-line octreotide-LAR therapy induces tumor shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trialClin Endocrinol (Oxf)200664334235116487447
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRAuriemmaRSPredictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patientsJ Clin Endocrinol Metab20069162112211816537687
   PubMed Web of Science ®Google Scholar
• RonchiCLBoschettiMDegli UbertiECItalian Multicenter Autogel Study Group in AcromegalyEfficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyClin Endocrinol (Oxf)200767451251917555511
   PubMed Web of Science ®Google Scholar
• ColaoAPivonelloRAuriemmaRSGrowth hormone-secreting tumor shrinkage after 3 months of octreotide-LAR therapy predicts the response at 12 monthsJ Clin Endocrinol Metab20089393436344218593770
   PubMed Web of Science ®Google Scholar
• AttanasioRLanziRLosaMEffects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter studyEndocr Pract200814784685518996812
   PubMedGoogle Scholar
• ColaoAAuriemmaRSReboraASignificant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegalyClin Endocrinol (Oxf)200971223724519094074
   PubMed Web of Science ®Google Scholar
• ColaoABronsteinMDFredaPPasireotide C2305 Study GroupPasireotide versus octreotide in acromegaly: a head-to-head superiority studyJ Clin Endocrinol Metab201499379179924423324
   PubMed Web of Science ®Google Scholar
• BrunsCLewisIBrinerUMeno-TetangGWeckbeckerGSOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileEur J Endocrinol2002146570771611980628
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoAMelmedSPasireotide – a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing’s diseaseIDrugs2007101288589518041687
   PubMed Web of Science ®Google Scholar
• GrassoLFPivonelloRColaoAInvestigational therapies for acromegalyExpert Opin Investig Drugs2013228955963
   PubMed Web of Science ®Google Scholar
• CarmichaelJDLanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsPatient Prefer Adherence20126738222298946
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals CorporationSandostatin LAR^® Depot (Octreotide Acetate for Injectable Suspension)2011
   Google Scholar
• Novartis Pharmaceuticals CorporationSignifor Prescribing Information2012 Available from: http://www.pharma.us.novartis.com/cs, http://www.pharma.us.novartis.com/product/pi/pdf/signifor.pdf
   Google Scholar
• CoxDStoneJManaging self-injection difficulties in patients with relapsing-remitting multiple sclerosisJ Neurosci Nurs200638316717116817668
   PubMedGoogle Scholar
• VermeireEHearnshawHVanRPDenekensJPatient adherence to treatment: three decades of research. A comprehensive reviewJ Clin Pharm Ther200126533134211679023
   PubMed Web of Science ®Google Scholar
• DimatteoMRVariations in patients’ adherence to medical recommendations: a quantitative review of 50 years of researchMed Care200442320020915076819
   PubMed Web of Science ®Google Scholar
• FraserCHadjimichaelOVollmerTPredictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosisJ Neurosci Nurs200133523123911668881
   PubMedGoogle Scholar
• FraserCHadjimichaelOVollmerTPredictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosisJ Neurosci Nurs200335316317012830664
   PubMedGoogle Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• TurnerAPKivlahanDRSloanAPHaselkornJKPredicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs modelMult Scler20071391146115217967842
   PubMed Web of Science ®Google Scholar
• ZolnierekKBDimatteoMRPhysician communication and patient adherence to treatment: a meta-analysisMed Care200947882683419584762
   PubMed Web of Science ®Google Scholar
• HortensiusJKarsMCWierengaWSKleefstraNBiloHJvan der BijlJJPerspectives of patients with type 1 or insulin-treated type 2 diabetes on self-monitoring of blood glucose: a qualitative studyBMC Public Health20121216722397638
   PubMed Web of Science ®Google Scholar
• KesselsRPPatients’ memory for medical informationJ R Soc Med200396521922212724430
   PubMed Web of Science ®Google Scholar
• KaliaLVO’ConnorPWSeverity of chronic pain and its relationship to quality of life in multiple sclerosisMult Scler200511332232715957515
   PubMed Web of Science ®Google Scholar
• StormannSSchopohlJEmerging drugs for acromegalyExpert Opin Emerg Drugs2014191799724400774
   PubMed Web of Science ®Google Scholar